Morgan Stanley Raises TMO Price Target to $730

Morgan Stanley maintains its Overweight rating on Thermo Fisher Scientific with a new price target of $730, a 6.54% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 1:56 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Morgan Stanley raised its price target on Thermo Fisher Scientific Inc. ($TMO) to $730 from $650 on October 13, 2026, and rates the stock "Overweight".

Since the rating, $TMO is up 4.1% to date (from the $663.04 close on Oct 13, 2026).

TMO Thermo Fisher Scientific Inc.

$690 +16.77% year to date

Daily close · Oct 16, 2026

Key Points

On October 13, 2026, Morgan Stanley reiterated its Overweight rating on Thermo Fisher Scientific Inc. with a price target of $730, up from $650.
Morgan Stanley's $730 price target implies 6.54% upside from Thermo Fisher Scientific Inc.'s ($TMO) current $685.18 share price.
The stock is currently trading at $685.18 as of October 16, 2026, which is 6.1% below the new target.
Thermo Fisher has a trailing revenue of $46.34 billion and a net margin of 15%.

Get $TMO trade alerts by text

We text you when insiders, Congress or big funds trade $TMO. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Thermo Fisher Scientific Inc. alert may contain errors. Disclosures

Morgan Stanley has reaffirmed its Overweight rating on Thermo Fisher Scientific Inc. (NYSE: TMO) on October 13, 2026, raising its price target from $650 to $730. This marks a significant adjustment in their outlook for the company, reflecting confidence in its future performance. The stock is currently trading at $685.18 as of October 16, 2026, which is about 6.1% below the new target price.

Other Institutional Activity in Thermo Fisher Scientific

Several other institutional investors have also adjusted their stakes in Thermo Fisher. Blackrock Inc. increased its holdings by 492,913 shares, bringing its total to about 30.9 million shares valued at $21.33 billion. Meanwhile, FMR, LLC added 3.3 million shares, ending with roughly 14.1 million shares worth about $9.72 billion. State Street Corporation slightly boosted its position with an increase of 93,700 shares, totaling approximately 16.8 million shares valued at $11.61 billion.

Thermo Fisher Scientific Inc. Stock Down 1.6%

Thermo Fisher's stock is currently trading near $685.18, which is below the recent price target set by Morgan Stanley. The company has shown strong performance with a trailing revenue growth of 10.5% year-over-year. This context is important as investors consider the stock's potential upside based on the new target.

12-month forecast

$TMO price target

Thermo Fisher Scientific Inc. daily closes and this analyst's $730 target. Not advice.

Recent Earnings

Thermo Fisher reported trailing twelve-month revenue of approximately $46.34 billion, with earnings per share (EPS) of $18.57. The company has a net margin of 15% and a return on equity (ROE) of 13.5%. Its next earnings report is scheduled for October 21, 2026.

Dividend

Thermo Fisher pays an annual dividend of $1.88 per share, which gives a yield of about 0.3%. The company has a dividend payout ratio of 9.7%, indicating a solid balance between rewarding shareholders and reinvesting in growth.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Insiders have been active recently, with several significant sales. Lisa P Britt, an officer, sold 11,440 shares on August 19, 2026, valued at about $7.01 million. CEO Marc N. Casper sold 20,000 shares on August 21, 2026, totaling approximately $12.56 million. Additionally, he sold 275 shares on August 24, 2026, valued at around $172,439. President Gianluca Pettiti sold 4,133 shares on August 31, 2026, with a total value of approximately $2.54 million.

Analysts Set New Price Targets

On October 13, 2026, Morgan Stanley maintained its Overweight rating on Thermo Fisher with a price target of $730. This follows Barclays, which also maintained an Overweight rating but with a slightly higher target of $750 on October 7, 2026. Meanwhile, CLSA initiated coverage with an Outperform rating and a target of $748 on September 3, 2026. The consensus target among analysts currently stands at $730, reflecting confidence in the company's growth potential.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is a global leader in providing life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products. The company operates in various segments, including Life Sciences Solutions and Analytical Instruments, helping customers in research, diagnostics, and biopharma services. With a strong revenue base and a focus on innovation, Thermo Fisher continues to be a key player in the healthcare sector.

Bottom Line

Investors will be watching Thermo Fisher closely, especially with its next earnings report due on October 21, 2026. The recent adjustments in analyst ratings and price targets suggest a positive outlook for the company, despite the current stock price being below the new target set by Morgan Stanley.